Enterprise Value
-7.894M
Cash
25.33M
Avg Qtr Burn
-2.835M
Short % of Float
0.98%
Insider Ownership
1.12%
Institutional Own.
13.31%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
APVO436 (anti-CD123 x anti-CD3) Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer | Phase 1b Data readout | |
ALG.APV-527 Details Cancer, Solid tumor/s | Phase 1 Data readout |